alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23

                          Independent Auditors' Consent

The Board of Directors
IMPATH Inc.:

We consent to the incorporation by reference in the Registration Statements on
Form S-3 (no.'s 333-47903 333-45921 and 333-62563) and on Form S-8 (no.'s
333-96867, 333-09469, 333-81816, 333-66596, 333-36454 and 333-47689) of IMPATH
Inc. of our report dated February 28, 2003, except as to the second paragraph of
note 9 to the consolidated financial statements, which is as of March 31, 2003,
with respect to the consolidated balance sheets of IMPATH Inc. and subsidiaries
as of December 31, 2002 and 2001 and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the years in the
three-year period ended December 31, 2002, and the related consolidated
financial statement schedule, which report appears in the December 31, 2002
annual report on Form 10-K of IMPATH Inc.

Our report on the consolidated financial statements refers to the Company's
adoption of Statement of Financial Accounting Standards No. 142 "Goodwill and
Other Intangible Assets" effective January 1, 2002 and Statement of Financial
Accounting Standards No. 141, "Business Combinations", effective July 1, 2001.

                                                    KPMG LLP

Short Hills, New Jersey
May 5, 2003
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Neurological Disorders and Stroke Special Emphasis Panel; NINDS Contract Technical Evaluation.                    

*Date:*                         January 18, 2022.                    

*Time:*                         10:00 a.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).                    

*Contact Person:*                         Marilyn Moore-Hoon, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, 301-827-9087,                         *mooremar@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 4, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-00134 Filed 1-7-22; 8:45 am]

BILLING CODE 4140-01-P
Fourth Court of Appeals

San Antonio, Texas

May 21, 2019

No. 04-19-00236-CV

IN RE GUARDIANSHIP OF CHARLES INNESS THRASH, AN ADULT,

From the Probate Court No 1, Bexar County, Texas

Trial Court No. 2017PC2912

Honorable Oscar J. Kazen, Judge Presiding

O R D E R

The Appellees’ Unopposed Motion to Extend Time to File Brief is hereby GRANTED. 

Time is extended to July 29, 2019. 

_________________________________

Irene Rios, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 21st day of May, 2019.

___________________________________

KEITH E. HOTTLE,

Clerk of Court
**  Exhibit 23.1**

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

We hereby consent to theincorporation by reference in the Registration Statement on Form S-8 (Nos.333-107988, 333-101828, 333-74610, 333-59843, 333-37111, 333-49350, 333-52598)of Zoran Corporation of our report dated March 31, 2005 relating to thefinancial statements, and management’s assessment of the effectiveness ofinternal control over financial reporting and the effectiveness of internalcontrol over financial reporting, which appears in this Form 10-K.

 

 

/s/ PricewaterhouseCoopers LLP

San Jose, California

 

### **March 31, 2005**

 

----
f8k06810ex10iv_cybra.htm


Exhibit 10.4














WAIVER AND CONFIRMATION












WHEREAS, the undersigned (the “Holder”) is a holder of 8% Convertible Debentures due April 10, 2009 (the “Debenture”) issued by CYBRA Corporation, a New York corporation (the “Corporation”); and







WHEREAS, pursuant to the Securities Exchange Agreement (the “Exchange Agreement”), dated as of April 10, 2009, between the Corporation and the Holder, the Holder has agreed to exchange the Debenture for the number of shares of the Corporation’s Series A 10% Convertible Preferred Stock (the “Preferred Stock”) set forth in the Exchange Agreement; and







WHEREAS, for purposes of certainty, the Holder wishes to (i) waive certain provisions of the Exchange Agreement and (ii) confirm the Exchange Agreement.







NOW THEREFORE, the Holder hereby agrees as follows:








	
1.  

	
Notwithstanding Section 11(c) of the Exchange Agreement, the Holder hereby irrevocably and unconditionally waives the expiration date of October 1, 2009 provided for in Section 3(b) of the Exchange Agreement.













	
2.  

	
The Holder hereby confirms that the Holder will proceed with the exchange of the 8% Convertible Debenture due April 10, 2009 issued by the Corporation for shares of the Preferred Stock in accordance with the terms of the Exchange Agreement.












IN WITNESS WHEREOF, the Holder has executed this Waiver and Confirmation effective as of the day and year written below.




 








	
                                                                                                HOLDER












By: ___________________



	
  

	
Name:








	
  

	
Date:
Exhibit
      32.2





CERTIFICATION
      PURSUANT TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





In
      connection with the Quarterly report of Quintek Technologies, Inc. (the
“Company”) on Form 10-QSB for the period ending December 31, 2006 as filed with
      the Securities and Exchange Commission on the date hereof (the “Report”), I,
      Andrew Haag, Acting Chief Financial Officer of the Company, certify, pursuant
      to
      18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:





|(1) | The
              Report fully complies with the requirements of section 13(a) or 15(d)
              of
              the Securities and Exchange Act of 1934; and
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------




|(2) | The
              information contained in the Report fairly presents, in all material
              respects, the financial condition and result of operations of the
              Company.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




A
      signed
      original of this written statement required by Section 906 has been provided
      to
      Quintek Technologies, Inc. and will be retained by Quintek Technologies, Inc.
      and furnished to the Securities and Exchange Commission or its staff upon
      request.





Date:
                February 20, 2007
            By:*/s/
                ANDREW HAAG*Andrew
                HaagChief
                Financial Officer
#### David GARRISON *v.*STATE of Arkansas

CR 74-101

515 S.W. 2d 222

Opinion delivered October 21, 1974

[Rehearing denied December 2, 1974.]

*Adams & Covington,*for appellant.

*Jim Guy Tucker,*Atty. Gen., by: *Gary Isbell,*Asst. Atty. *139Gen., for appellee.

Conley Byrd, Justice.

Appellant David Garrison’s sole contention for reversal of his two year conviction and sentence for possession of a controlled substance (LSD) is that the trial court should have excluded under the Fourth Amendment, as an illegal search, any evidence of the drugs that he voluntarily delivered to a confidential informant and an undercover narcotics agent. We find no merit in the contention. See *Lewis*v. *United States,*385 U.S. 206, 87 S. Ct. 424, 17 L. Ed. 312 (1966).

Affirmed.
EXHIBIT 32.0

                                  CERTIFICATION

      Pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley
Act of 2002

Each of, Edward J. Molnar, Chief Executive Officer and Brendan J. McGill, Senior
Vice President and Chief Financial Officer, of Harleysville Savings Financial
Corporation (the "Company"), hereby certify, pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1)   The Quarterly Report on Form 10-Q of the Company for the fiscal quarter
      ended December 31, 2004 (the "Report") fully complies with the
      requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
      1934 (15 U.S.C. 78m(a) or 78o(d)); and

(2)   The information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.

                                           By:   /s/ Edward J. Molnar
                                                 --------------------
                                                 Edward J. Molnar
                                                 Chief Executive Officer


                                            By:  /s/ Brendan J. McGill
                                                 ---------------------
                                                 Brendan J. McGill
                                                 Senior Vice President and
                                                 Chief Financial Officer

Date: February 14, 2005

Note: A signed original of this written statement required by Section 906 of the
      Sarbanes-Oxley Act has been provided to Harleysville Savings Financial
      Corporation and furnished to the Securities and Exchange Commission or its
      staff upon request.
**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-161163, 333-152576, 333-127354, 333-107988, 333-101828, 333-74610, 333-52598, 333-49350, 333-59843, 333-37111, and 333-20225 on Form S-8 of our report datedMarch 1, 2010, relating to the consolidated financial statements of Zoran Corporation and its subsidiaries (collectively the “Company”), and the effectiveness of the Company’s internal control over financial reporting, appearingin this Annual Report on Form 10-K of Zoran Corporation for the year ended December 31, 2009. 

/s/ DELOITTE & TOUCHE LLP 

San Jose, California 

March 1, 2010
X-Ray & Interventional Industry: Review of Proposed 

Accessibility Standards

U.S. Access Board

May 8, 2012

Atlanta Georgia

Tony Roder, Dir. Regulatory Affairs, GE Healthcare

Vice Chair MITA X-Ray Section

Chair COCIR CT Group

Diagnostic Equipment: X-Ray & Interventional

 General Considerations

o Committed to enabling access for all patients

o Prescription use devices, required to balance safety, effectiveness, quality, 

access and utility in a clinical setting

o Generally large capital equipment

o Stakeholder coordination is key to effective solutions

[Photo: Woman using a wheelchair being assisted in preparation of an x-ray of her arm.]

Current Accessibility

 Interventional Equipment

o Fixed

 Patients sedated & transferred from gurney/stretcher

o Mobile

 C-arm brought into position around patient

 X-Ray Equipment

o Fixed

 Digital detector flexibility & some technical limitations

o Mobile

 System brought into position around patient

[Photo: Medical personnel and patient shown at machine with x-ray unit that can be 

positioned around patient.]

Example Accessories / Optional Equipment

 Wheelchair ramps

 Wireless/non-tethered detectors (use anywhere in room)

 Adjustable footrests

 Rails

 Hand grips

 Compression bands

 Shoulder blocks
 Support pads

[Photo: Several images of unidentified adjustable equipment components.]

Example Technical Limitations

 Minimum table height 

o X-ray tube / x-ray detector located underneath tabletop.

[Photo: X-ray machine with scanning bed on which the x-ray detectors, overhead tube, and 

under-table tube are identified.]

Recommendations & Next Steps

 Committed to enabling accessibility options for all patients.

 Manufacturers bring a unique perspective.

o Technical implications & possibilities

o Clinical use & applications 

 Advisory Committee engagement

o All stakeholders
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity Review.                    

*Date:*                         February 4, 2022.                    

*Time:*                         3:00 p.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Video Meeting).                    

*Contact Person:*                         Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, Division of Extramural Activities, NIDDK, National Institutes of Health, Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 594-8898,                         *barnardm@extra.niddk.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: January 7, 2022. 

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-00477 Filed 1-12-22; 8:45 am]

BILLING CODE 4140-01-P
Case 1:00-cr-00090-SSB Document 105 Filed 11/08/2007 Page 1 of 3
Case 1:00-cr-00090-SSB Document 105 Filed 11/08/2007 Page 2 of 3
Case 1:00-cr-00090-SSB Document 105 Filed 11/08/2007 Page 3 of 3
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0001003130
<NAME> LCA-VISION INC.
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                              JAN-1-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                             841
<SECURITIES>                                         0
<RECEIVABLES>                                    1,166
<ALLOWANCES>                                       100
<INVENTORY>                                        268
<CURRENT-ASSETS>                                 3,022
<PP&E>                                          12,754
<DEPRECIATION>                                   3,442
<TOTAL-ASSETS>                                  13,682
<CURRENT-LIABILITIES>                            8,068
<BONDS>                                          4,737
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      2,522
<COMMON>                                            79
<OTHER-SE>                                     (3,224)
<TOTAL-LIABILITY-AND-EQUITY>                    13,682
<SALES>                                             17
<TOTAL-REVENUES>                                 2,762
<CGS>                                               10
<TOTAL-COSTS>                                    1,871
<OTHER-EXPENSES>                                 2,455
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 236
<INCOME-PRETAX>                                (1,784)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,784)
<EPS-PRIMARY>                                   (0.09)
<EPS-DILUTED>                                   (0.09)


</TABLE>
Exhibit 32.2

                    CERTIFICATION OF CEO AND CFO PURSUANT TO
                               18 U.S.C. ss. 1350,
                             AS ADOPTED PURSUANT TO
                    ss. 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection  with the Quarterly  Report on Form 10-QSB of Dialex Minerals Inc.
(the Company) for the quarter  ended June 30, 2004 as filed with the  Securities
and Exchange  Commission on the date hereof (the Report), I, L. Kirk Boyd, Chief
Financial Officer of the Company,  hereby  certifies,  pursuant to 18 U.S.C. ss.
1350, as adopted pursuant to ss. 906 of the  Sarbanes-Oxley  Act of 2002, to the
best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and result of operations of the Company.

By:                                    /s/ L. Kirk Boyd
                                      ----------------------------------
                                           L. Kirk Boyd
                                           Chief Financial Officer
                                           August 16, 2004

This  certification   accompanies  this  Report  pursuant  to  ss.  906  of  the
Sarbanes-Oxley  Act of 2002 and shall not,  except to the extent required by the
Sarbanes-Oxley  Act of 2002,  be deemed filed by the Company for purposes of ss.
18 of the Securities Exchange Act of 1934, as amended.
EXHIBIT 23.1




CONSENT OF INDEPENDENT ACCOUNTANTS




We consent to the incorporation by reference in the registration statement of
Pharmaceutical Product Development, Inc. and its subsidiaries on Form S-8 (File
No. 333-20925) of our report dated February 2, 1999, on our audits of the
consolidated financial statements of Pharmaceutical Product Development, Inc.
and its subsidiaries as of December 31, 1998 and 1997 and for each of the three
years in the period ended December 31, 1998, which report is included in this
annual report on Form 10-K.




PRICEWATERHOUSECOOPERS LLP


Raleigh, North Carolina
March 3, 1999
IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF OHIO
WESTERN DIVISION

Terry Walker,
Plaintiff(s),
Case Number: 1:1 7ev575
vs.
Judge Susan J, Dlott
City of Cincinnati Department of Building
and Inspections, et al.,
Defendant(s).
ORDER

The Court has reviewed the Report and Recommendation of United States Magistrate Judge
Karen L. Litkovitz filed on November 8, 2017 (Doc. 6), to whom this case was referred pursuant to
28 U.S.C. §636(b), and noting that no objections have been filed thereto and that the time for filing
such objections under Fed. R. Civ. P. 72(b) expired November 18, 2017, hereby ADOPTS said
Report and Recommendation.

Accordingly, plaintiffs complaint is DISMISSED with prejudice.

The Court certifies pursuant to 28 U.S.C. §1915(a) that for the foregoing reasons an appeal of
any Order adopting the Report and Recommendation will not be taken in good faith, therefore,
denying plaintiff leave to appeal in forma pauperis. Plaintiff remains free to apply to proceed in
forma pauperis in the Court of Appeals. See Callihan v. Schneider, 178 F.3d 800, 803 (6" Cir. 1999),

overruling in part Floyd v. United States Postal Serv., 105 F.3d 274, 277 (6" Cir. 1997).

IT IS SO ORDERED.

_ctenten 4 1 ie

Judge Susan J. Dlo'
United States Distric?Court
IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF OHIO
EASTERN DIVISION

HOUSTON BYRD, JR.,
3 Case No. 2:17-CV-981
Plaintiff, :
JUDGE ALGENON L. MARBLEY
v. :
3 Magistrate Judge Jolson
JUDGE W. SCOTT GWIN, :

Defendant.

ORDER

This matter comes before the Court on the Magistrate Judge’s November 16, 2017
Report and Recommendation (ECF No. 9), which recommended that Plaintiff's Motion for
Leave to Proceed in forma pauperis (ECF No. 6) be denied.

The Report and Recommendation specifically advised the parties that the failure to object
results in a waiver of the right to have the district judge review the Report and Recommendation
de novo, and also operates as a waiver of the right to appeal the decision of the District Court
adopting the Report and Recommendation. (ECF No. 9 at 3.) The parties have failed to file any
objections, and the deadline for objections (November 30, 2017) has lapsed.

The Court hereby ADOPTS the Report and Recommendation based on the independent
consideration of the analysis therein. The Motion for Leave to Proceed in forma pauperis is
hereby DENIED.

IT IS SO ORDERED.

s/ Algenon L. Marble:
ALGENON L. MARBLEY

UNITED STATES DISTRICT JUDGE

DATED: December 12, 2017